Serum Histatin Levels in COVID‐19: Association With Disease Severity and Immune Status
Journal of Medical Virology · 2026-06 · 98 (6)
DOI: 10.1002/jmv.71009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 10.06.2026. Verfasst von Umut Aydın und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine, İnönü University, Malatya, Turkey. Hauptthemen laut MEDLINE: Histatins, COVID-19. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Histatins are histidine‐rich antimicrobial peptides with emerging immunomodulatory properties; however, their systemic behavior across the clinical spectrum of COVID‐19 remains unknown. We aimed to characterize serum histatin levels in patients with mild COVID‐19 (without pneumonia) and severe COVID‐19 (with pneumonia) and to explore factors potentially associated with their variation. Ninety individuals were prospectively enrolled: healthy controls ( n = 30), patients with mild COVID‐19 (without pneumonia ( n = 30), and patients with severe COVID‐19 (with pneumonia receiving corticosteroid therapy ( n = 30). Serum histatin‐1, histatin‐3, and histatin‐5 concentrations were quantified by ELISA. Group comparisons were performed using Kruskal–Wallis and Mann–Whitney U tests; correlations were assessed using Pearson coefficients. Histatin‐1 did not differ among groups ( p = 0.161). Both histatin‐3 and histatin‐5 were significantly reduced in mild COVID‐19 compared with controls ( p = 0.004 and p = 0.002, respectively). Unexpectedly, patients with severe COVID‐19, all of whom were receiving corticosteroids, did not exhibit further histatin reductions; their levels were comparable to controls and significantly higher than the mild group (histatin‐3 p = 0.016; histatin‐5 p = 0.028). Histatin‐3 correlated significantly with ferritin ( r = 0.413; p = 0.009), D‐dimer ( r = 0.369; p = 0.021), and albumin ( r = −0.330; p = 0.018). SARS‐CoV‐2 infection without pneumonia was associated with significantly lower serum histatin‐3 and histatin‐5 levels. In contrast, histatin levels were preserved in patients with severe COVID‐19 and pneumonia who were receiving corticosteroid therapy. Because of the cross‐sectional design, this finding should be interpreted as an association rather than evidence of a treatment effect. The observed correlations between histatin‐3 and ferritin, D‐dimer, and albumin further suggest that histatin‐3 may be linked to acute‐phase and inflammatory responses during COVID‐19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Faculty of Medicine, İnönü University, Malatya, Turkey.
- Department of Intensive Care, Fethi Sekin City Hospital, Elazığ, Turkey.
- Department of Anatomy, Faculty of Medicine, Fırat University, Elazığ, Turkey.
- Department of Rheumatology, Faculty of Medicine, Fırat University, Elazığ, Turkey.
ORCID-Profile: Umut Aydın
Zitieren
APA
Aydın, U., Düzenci, D., Akkoç, R. F., & Karataş, A. (2026). Serum Histatin Levels in COVID‐19: Association With Disease Severity and Immune Status. Journal of Medical Virology, 98(6). https://doi.org/10.1002/jmv.71009
Vancouver
Aydın U, Düzenci D, Akkoç RF, Karataş A. Serum Histatin Levels in COVID‐19: Association With Disease Severity and Immune Status. Journal of Medical Virology. 2026;98(6). doi:10.1002/jmv.71009
BibTeX
@article{Aydn2026,
author = {Aydın, Umut and Düzenci, Deccane and Akkoç, Ramazan Fazıl and Karataş, Ahmet},
title = {Serum Histatin Levels in COVID‐19: Association With Disease Severity and Immune Status},
journal = {Journal of Medical Virology},
year = {2026},
volume = {98},
number = {6},
doi = {10.1002/jmv.71009}
}
EUVIMED